// App-Quantinova.ai

102 : Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

Researchers

Presenter

  • Robert Landewe

Principal Investigators

  • Martin Rudwaleit

  • Christian Stach

  • Bengt Hoepken

  • Pritibha Singh

  • Joachim Sieper

  • Desiree Van der Heijde

  • Maxime Dougados

  • Phillip Mease

  • John Reveille

  • Jessica Walsh

  • Alan Kivitz

  • Jurgen Braun

  • Atul Deodhar

Medical Centers

  • University of Alberta, Edmonton, AB, Canada

  • Berlin, Germany

  • Paris Descartes University, Paris, France

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

Locations

  • France

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved